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1. Introduction
1.1. The androgen receptor and CaP progression
The development and progression of prostate cancer (CaP) is largely dependent on the
dysregulation of the androgen/androgen receptor (AR) signaling pathway; though, the
mechanism of CaP progression remains elusive. Initial treatments for CaP included prosta‐
tectomy or radiation to destroy cancerous cells [1]. However, these treatments were not
curative and more often than not there were recurrences and metastases of the cancer. Mainstay
treatments that target the androgen/AR pathway through anti-androgen and androgen
ablation therapies have been promising; yet again, these therapies seem to fail as the tumor
progresses. This suggests that the androgen/AR dependence of CaP cells vary over time such
that alterations in androgen availability, AR sensitivity and receptor promiscuity fuel a more
aggressive CaP.
Approximately 80-90% of CaPs are originally androgen dependent (AD) at diagnosis [2].
Androgens stimulate the proliferation and inhibit the apoptosis of cells, thus implicating that
CaP cells require a certain level of androgens to maintain their proliferation and survival [1].
This is primarily the reason why androgen ablation therapy is initially successful—it removes
the stimulation these cells require for proliferation, ultimately causing the regression of the
tumor. However, over time patients often fail androgen ablation therapy as the tumor becomes
a more lethal androgen independent (AI) or castration resistant form. There is no effective
therapy for AI-CaP.
The prostate requires androgenic steroids for development and function. Testosterone is the
main circulating androgen and is secreted from the testes as well as the adrenal glands (adrenal
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steroid conversion). Once in the blood stream, the majority of the testosterone binds to albumin
and sex-hormone-binding globulin (SHBG) while a small fraction is freely dissolved within
serum. Within the prostate, testosterone is converted to a derivative, dihydrotestosterone
(DHT), by 5-alpha-reductase. DHT is a more potent and active form of testosterone and has a
greater affinity for the AR relative to testosterone. Testosterone and DHT bind to the AR and
causes its nuclear localization, transcriptional activation and its interaction with co-regulators/
co-activators to mediate AR-directed gene transcription [2].
The AR is required for the development of prostate carcinogenesis from early prostate
intraepithelial neoplasia (PIN) to organ-confined or locally invasive primary tumors [3]. As a
member of the steroid-thyroid-retinoid nuclear receptor superfamily of proteins, the AR is in
its inactive form within the cytoplasm, bound to heat shock proteins (HSP) [4-7] and compo‐
nents of the cytoskeleton [7,8], preventing AR nuclear localization and transcriptional activa‐
tion. The binding of DHT or testosterone causes a conformational change leading to the
dissociation of the AR from the HSPs and its subsequent phosphorylation [1, 9]. Once ligand
bound, the AR is stabilized within the cytoplasm and translocates to the nucleus. The andro‐
gen-AR complex is in a conformational state to now homodimerize within the nucleus and
bind to androgen response elements (AREs) in the promoter region of target genes [1] such as
prostate specific antigen (PSA), a routine biomarker for prostate cancer diagnosis and pro‐
gression [7, 10] and, probasin, a prostate-specific gene that has been exploited as a marker of
prostate differentiation [11]. The AR has both a cytoplasmic and nuclear distribution, and
shows a certain degree of trafficking either to or from the nucleus [12]. There are varying
reports on the subcellular distribution of the AR in different cell types; however, this two-step
model for steroid hormone receptor activation is a clear representation of ligand activated
translocation and the observed focal accumulations of the AR within the nucleus [12].
1.2. AR structure and function
The AR gene is located on the X chromosome (q11-12), and contains eight exons that produce
a protein of approximately 920 amino acids [7]. Exon 1 codes for the N-terminal domain (NTD),
exons 2 and 3 translate into the central DNA binding domain (DBD) which contains two zinc
fingers for specific binding of DNA sequences [1], and exon 4 to 8 code for a hinge region and
a conserved C-terminal ligand binding domain (LBD).
The NTD (1-558) is a poorly conserved region that houses important sequence motifs for AR
conformation and activity [7]. There are three regions of tri-nucleotide repeats, which include
poly-glutamine (Q) and poly-glycine tracts [7, 13]. The poly-Q tract is encoded by a polymor‐
phic CAG repeat [14]. The length of the repeats inversely affects the stability of the AR-NTD
and C-terminal LBD interaction, and, AR expression and activity [7, 15, 16]. CAG tri-nucleotide
repeats can vary between 11 and 31 repeats; less than 18 repeats are thought be an indicator
of CaP risk.
The NTD also contains the transcriptional activation function-1 (AF1) comprising two
transcriptional activation units (TAU): TAU-1 and TAU-5. The AF1 subdomain of the AR is
the predominant site for transactivation, where TAU-1 is required for ligand-dependent
transcription of the AR; TAU-5 is responsible for the majority of the constitutive activity
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associated with the NTD, and the recruitment of the Steroid Receptor Co-activator (SRC)/p160
family of co-activators. For example, TIF2 (Transcriptional Intermediary Factor 2), SRC-1, and
GRIP-1 are members of the SRC/p160 family which increase AR transcription through their
interactions with the NTD and DBD [4, 5, 7, 17]. These co-activators also recruit other co-
regulators such as histone acetyl transferase (HAT) activity containing enzymes such as cAMP
response element binding protein (CREB)-binding protein (CBP)/p300 and p300/CBP-
associated factor (p/CAF) to initiate chromatin remodeling [7, 18] in preparation for DNA
transcription [7, 19].
The LBD folds into 12 helices to form the ligand binding pocket. Interaction of ligands to the
LBD promotes AR stability by the formation of the C-terminal transcriptional activation
function -2 (AF2) domain and the subsequent interactions between the NTD/LBD [7]. The NTD
interacts with the LBD through its sequence motifs 23FQNLF27 and 433WHTLF437 [5, 7, 20], while
co-activators/co-regulators (E.g. SRC/p160 family of co-activators) bind to the LBD by a highly
conserved consensus sequence LXXLL (L is Leucine and X is any amino acid) motif (also known
as the NR box) [7]. The LBD LXXLL binding region primarily serves to recruit LXXLL motif
containing co-activators/co-regulators and structurally enables the NTD FXXLF containing
region to interact with the LBD [7]. The LXXLL motifs of such co-regulators form a two-turn
amphipathic α-helix which binds to the hydrophobic cleft of the LBD (specifically AF2) [21].
The LBD AF2 domain is comprised of helices 3, 4, 5 and 12 [22]. The ligand binding pocket is
formed by helices 3, 5, and 10. Helix 12 is thought to lie across the ligand binding pocket and
stabilize the ligand-AR interaction and increase ligand-activated transcription. The AR NTD
and C-terminal domain (CTD) interaction in conjunction with Helix 12 serve to stabilize
agonist ligand binding and receptor transcriptional activity [23]. Furthermore, the interaction
of AR-interacting proteins or co-regulators such as androgen receptor co-activator, ARA70,
(which binds to both the AR-DBD and AR-LBD) can increase the receptivity of the AR-LBD to
other activating ligands such as hydroxyflutamide (non-steroidal anti-androgen) and estro‐
gens [7, 24-26]. However, it was shown that the AR NTD and CTD interaction was not
absolutely required for transcriptional activity. For example, ligands used at high concentra‐
tions and peptides that blocked the NTD and CTD interaction did not absolutely inhibit
transcriptional activity of the AR [23, 27, 28].
The AR is opposed by co-repressors which inhibit its transcriptional activation. Nuclear
receptor co-repressor (NCor) and silencing mediator for retinoid and thyroid hormone
receptors (SMRT) disrupts the NTD-LBD interaction and the binding of SRC/p160 co-activators
[7]. NCor and SMRT are able to recruit histone deacetylases (HDAC) to promote the repack‐
aging of DNA and prevent the binding of transcriptional machinery, activators, and receptors
[7, 29]. However, NCor requires the presence of a ligand (agonist or antagonist) whereas SMRT
is able to mediate its effects in the presence or absence of ligands [7, 29-31]. The LBD also houses
the nuclear export signal (NES) (amino acids 742-817) and the nuclear localization sequence
(NLS), found at the junction between the hinge region and DBD (50 amino acids, 625-676) [7].
Upon ligand binding the NES becomes inactive and the NLS is bound by co-activators such
as Filamin-A and importin-α. These interactions direct the nuclear localization of the AR [6, 7,
26, 31, 33, 34, 35]. Upon the loss of ligand interactions, the NES co-ordinates the shuttling of
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the AR to the cytoplasm where AR can tether to cytoskeletal proteins to again prepare for
ligand binding [5,7].
The DBD (559-624) is comprised of two zinc fingers domains created by three α-helices and
a 12 amino acid C-terminal extension [1]. The first zinc finger contains a P-Box motif for
specific nucleotide interactions and the second, a D-Box motif which functions as a DBD/DBD
site for receptor homodimerization [7]. It is thought that Lysine (Lys;K) 580 and Arginine
(Arg;R) 585 in the first zinc finger bind respectively to the second and fifth nucleotide pairs
in the first ARE repeat: GGTACA [22, 36-39]. The second zinc finger stabilizes the binding
complex by making hydrophobic interactions with the first zinc finger and contributes to the
specificity of receptor DNA binding [22, 39]. Due to the similarity of the hormone response
elements (HREs) of the nuclear receptor family, there is an overlap of nucleic acid sequen‐
ces in which these receptors can bind. Steroid receptors recognize a palindromic sequence
spaced by three nucleotides [40]. The AR, glucocorticoid, mineralcorticoid and progester‐
one receptors recognize the 5’-TGTTCT-3’ core sequence [40]. However, it has been found
that ARs can also recognize specific AREs that consist of two hexameric half-sites separat‐
ed  by  3  base  pairs  [41-45].  Although  ligand  specificity  brings  about  hormone  specific
responses, the specificity of hormone receptors has been questioned as each receptor can bind
to similar or the same sequence [45]. It is thought that protein-protein interactions play a role
in discriminating AR and other steroid mediated effects [46, 47] to enable ARE dependent
gene transcription rather than the activation of other HREs.
1.3. AR and post translational modifications
Despite the AR’s role in genomic upregulation of androgen dependent gene transcription, its
activation can signal through alternative means at the plasma membrane and cytoplasm
(referred to as non-genomic signaling) [1]. For example, the AR can trigger intracellular
calcium release and the activation of protein kinases such as the Mitogen Activated Protein
Kinases (MAPK), Protein Kinase A (PKA), AKT and PKC [7]. Phosphorylation of the AR by
MAPK, JNK, AKT, ERK, p38, increases AR response to low level of androgens, estrogens, and
anti-androgens as well as enhances the recruitment of co-activators [7]. Furthermore, the AR
itself is a downstream substrate for phosphorylation by receptor-tyrosine kinases and G-
protein coupled receptor signaling. The phosphorylation of AR is mediated by the recruitment
of kinases in the presence or absence of androgens. Phosphorylation at Serine (Ser) residues,
Ser80, Ser93, and Ser641 is thought to protect the AR from proteolytic degradation [7, 48].
Alternatively, AR degradation is regulated by the phosphorylation of specific residues
recognized by E3 ubiquitin ligase. For example, MDM2 E3 ubiquitin ligase promotes polyu‐
biquitylation of the AR by recognizing AKT dependent phosphorylated serine [3,49]. More‐
over, transactivation of the AR largely relies upon the phosphorylation of Ser213, Ser506, and
Ser650 [7]. Phosphorylation of the AR is required for its effects within the nucleus and the AR
should remain hyperphosphorylated to mediate its transcriptional role [3]. Studies have also
shown constitutive phosphorylation of the AR at Ser94 as well as on other serine residues such
as Ser16, 81, 256, 309, and 424. The loss of phosphorylation results in the loss of transcriptional
activity and nuclear localization [3, 50-52]. Specifically, Yang et al., (2005) demonstrated that
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dephosphorylation of AR at the NTD by protein phosphatase 2A (PP2A), resulted in the loss
of AR activity.
The AR receptors can also be acetylated, and sumoylated. These types of post translational
modifications have also been shown to affect receptor stability and activity. The KXKK motif
of the hinge region is a site for acetylation. Mutations of lysine to alanine reduced the tran‐
scriptional activity of AR by favoring NCoR interactions [3, 53]. Sumoylation of the AR is
hormone dependent and competes with ubiquitination of lysine residues. Sumoylation is
thought to repress AR activity. Disruption of sumoylation on Lys386 and Lys520 resulted in
an increase in AR transactivation [3, 54].
1.4. AR in CaP progression
The efficacy of many CaP treatments is often temporary, as CaP cells often become refractory
to hormone ablation therapies. The current therapeutics are largely targeted towards the
inhibition of AR activation, such as anti-androgens, chemical castration (treatment with
gonadotropin releasing hormone (GnRH) super agonists to inhibit testosterone secretion from
the testes), or surgery (orchidectomy) [7]. AI-CaP or castration resistant CaP is thought to occur
due to the androgen deprivation therapies as they may induce altered protein activity and
expression in the cancer cells. Despite androgen blockade in AI-CaP patients, expressions of
AR target genes such as PSA remain high. Furthermore, hormone refractory CaP continues to
rely on AR expression, suggesting that the AR is necessary to maintain proliferative and anti-
apoptotic effects. Therefore, CaP acquires the phenotype of oncogenic addiction to the AR for
its continued growth and resistance to therapy. The progression of CaP from an hormone
sensitive AD to a hormone resistant AI state is likely due to mechanisms involving alterations
in AR expression, amplification, mutations, and/or AR activity.
AR mutations in primary CaP are relatively low when compared to metastatic CaP where
frequencies are as high as 50% [1, 55-57]. Germline or somatic mutations of the AR leads to AR
overexpression and hypersensitivity due to point mutations and promiscuous mutant AR
proteins. Germline mutations of the AR are rarely found. Familial inheritance of CaP with at
least two first degree relatives account for 20% of cases and transmission compatible with
Mendellian inheritance is described to be 50% of the cases observed [3]. Genetic susceptibility
seems to be more significant in patients <55 years old [3]. Recently, a R726L mutation was
reported in only Finnish patients with sporadic or familial CaP [3, 58, 59]. Genomic alterations
to the AR have been found in both non-coding and coding sequences such as polymorphisms
of CAG and GGC repeats, single nucleotide polymorphisms, as well as silent and missense
mutations [3, 58, 60, 61]. Koochekpour et al., (2010) screened 60 CaP patients of African-
American and Caucasian families with a history of familial CaP. Using exon-specific PCR, bi-
directional sequencing and restriction enzyme genotyping, they found that one African-
American family had a novel germline AR misssense mutation (exon 2 of DBD A1675T; T559S)
in three siblings with early onset CaP. This mutation was transmitted in an X-linked pattern
and located at the N-terminal region of the DBD. Koochekpour et al., (2010) reason that the
location of this particular mutation likely affected AR ligand binding.
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Somatic mutations are largely single base substitutions: 49% at the LBD, 37% at the NTD, and
7% at the DBD [3]. For those CaP that harbor gain of function mutations the result is primarily
an increase in ligand promiscuity. The AR is activated by testosterone and DHT; however,
mutations in the LBD make the AR less stringent of its partners. For example, in LNCaP cells,
a Threonine (Thr; T) to Alanine (Ala;A) mutation (T877A) caused the expansion of ligand
binding activity [1, 8]. This mutation permitted AR activation by androgens, estrogens,
progesterones as well as the non-steroidal antagonist, flutamide. A study by Gaddipati et al.,
(1994) found that 25% of patient metastatic tumors had a T877A mutation. Patients that were
treated with flutamide often experienced a worsening of symptoms over time. Once flutamide
was withdrawn, patients tended to do better. Interestingly, some patients also experienced a
rise in serum PSA levels upon flutamide treatment. Taplin et al., (1999) studied patients that
were on flutamide treatment relative to those that were not given this particular treatment.
Tumor cells that had the T877A mutation increased in proliferation while patients who were
not treated with flutamide harboured different mutations of the AR that were not activated
by flutamide. Therefore, there seems to be a strong selective pressure for AR mutants arising
from flutamide treatment such that discontinuation of flutamide resulted in tumor regression
before growth resumed again. Other mutations such as the H874Y (Histadine to Tyrosine)
mutation in the CWR22 cell line have been found to affect co-activator interactions by altering
the conformation of Helix 12 of the LBD. Helix 12 regulates co-activator binding and creates a
specific groove with helices 3, 4, and 5 [63-67]. Helix 12 rotates over the ligand binding pocket
and assumes favorable or unfavorable positions depending on agonist or antagonist binding,
respectively. Helix 12 mutations have also been detected in CaP patients, such as Q902R
(Glutamine to Arginine), and M894D (Methionine to Aspartic Acid) (an androgen insensitive
mutation) [56, 67, 68]. The importance of Helix 12 and the NTD-LBD interaction for AR activity
is underscored by the fact that spontaneous mutations in Helix 12, NTD, and LBD caused either
complete or partial androgen insensitivity [67, 68]. Additionally, a L701H mutation was also
identified in conjunction with the T877A mutation in MDA CaP 2a cell lines [1, 69]. L701H
mutation alone decreased the ability of AR to bind DHT, but increased binding of other non
specific adrenal corticosteroids. The presence of the T877A mutation together with L701H
potentiated this interaction by more than 300% as both mutations were located within the LBD
[1, 70]. Hence, the susceptibility of the AR to minimize its ligand specificity in AI-CaP makes
AR dependent disease progression difficult to treat. On the other hand, other anti-androgens
such as Casodex (bicalutamide) do not seem to have the same response to T877A AR [1]. Novel
truncated AR mutant, mRNA splice variants and mutant AR lacking exon 3 (coding for C-
terminal portion of the DBD) tandem duplication have also been found in the 22RV1 cell line
(AI-CaP), derived from the CWR22R cell line [3, 71]. Furthermore, an important study by Han
et al., (2001) demonstrated that prostate tumors from a genetically engineered mouse model
upon androgen ablation resulted in AR gene mutations within AR NTD. Specifically, amino
acid substitution A229T and E231G (Glutamic Acid to Glycine) within the AR NTD signature
motif: ARNSM (Ala-Arg-Asn-Ser-Met), increased ligand independent basal activity, whereas,
E231G increased responsiveness to androgen receptor co-activator ARA160 and ARA70. The
ARNSM motif is unique to the AR and the most highly conserved region of the AR NTD.
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Another possible mechanism for the progression of AI disease is mediated by AR amplifica‐
tion. Overexpression of the AR causes hypersensitivity of the AR under low levels of andro‐
gens. Visakorpi et al., (1995) were the first to show that the AR was amplified in 305 hormone
refractory tumors subsequent to androgen ablation therapy. Although these tumors were
clinically presenting as AI-CaP, there was increased levels of the AR, and, continued prolifer‐
ation of the tumor still required androgen. This suggested that some AR amplified tumors may
require the presence of residual androgens that remain in the serum after monotherapy [1,
74]. Similarily, mouse models of CaP progression characterized by high expression of AR,
increased AR stability, and AR nuclear localization, had hypersensitive tumor growth
promoting effects upon DHT administration. DHT concentrations of 4 orders of magnitude
lower were able to stimulate growth relative to DHT levels required for AD LnCaP cell
proliferation [1, 75].
Although AR gene amplification and hypersensitivity serves to be a sound model for AI-CaP
progression, the AR may be activated by alternative means including activation by co-
regulators, increased androgen production, and/or intermediary downstream signaling
pathways. Greater levels of co-activator expression such as SRC-1, ARA70, and TIF2 were
demonstrated to be elevated in CaP and correlated with increased CaP grade, stage, and
decreased disease free survival. For example, Cdk-activating phophatase B, an identified co-
activator of the AR was overexpressed and also highly amplified in tumors with high Gleason
scores [3]. Local production of androgens within the prostate can also increase AR transacti‐
vation by compensating for decreased serum testosterone resulting from androgen ablation
therapy. Studies have shown that serum testosterone levels can decrease 95%, contrasting the
DHT levels within prostate tissue which only reduce by 60% [1, 76]. Locke et al., (2008)
demonstrated that there was de novo and organ synthesis of androgens in LNCaP xenograft
mouse models, suggesting that CaP cells had steroidogenic properties that enable them to
survive in androgen depleted environments. Moreover, this was also indicative of greater
levels of intratumoral 5-alpha-reductase activity. It is likely then, that during AI-CaP disease
progression, there is a switch in androgen source whereby testicular androgens are replaced
by prostatic androgen. Bennett et al., (2010) have deemed this as ‘androgen self-sufficient’.
There is also a hypothesis that conversion of adrenal steroids can sustain the androgen signal
by supplying adrenal androgens such as DHEA and androstenedione [78]. After castration,
adrenal androgens could account for as much as 40% of the total DHT in the prostate [76, 78].
Hormone receptors that are activated by ligand independent mechanisms are known as
‘outlaw’ receptors [1]. Certain growth factors such as Insulin Growth Factor (IGF)-1, Kerati‐
nocyte Growth Factor (KGF), and Epidermal Growth Factor (EGF) have been demonstrated
to activate AR and induce the expression of AR target genes. Culig et al., (1994) showed that
there was a 5-fold increase in PSA levels in LNCaP cells upon IGF-1 stimulation. Moreover,
the addition of Casodex abolished the activation of the AR by IGF-1, KGF and EGF, indicating
that the LBD was necessary for this activation. Overexpression of these growth factors has been
observed in CaP; however, it is unclear whether it is the AR pathway or indirect downstream
effects that are mediating tumorigenesis. In fact, patients with AI-CaP can fail Casodex therapy
suggesting that other mechanisms are in play for ligand independent activation of the AR.
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Furthermore, patients who received androgen ablation therapy have tumor cells that overex‐
press growth factor receptors, the receptor tyrosine kinases. Craft et al., (1999) demonstrated
that an AI-CaP cell line, generated from xenografts implanted in castrated mice, consistently
overexpressed Her-2/neu (from the EGF receptor family of receptor tyrosine kinases) [1].
Interestingly, AD-CaP cell lines could also be converted to AI-CaP cells by overexpressing
Her-2/neu. This pathway was not blocked by Casodex, which indicated that the LBD of the
AR was not necessary to transduce the effects of Her-2/neu. Although Trastuzumab (Hercep‐
tin) is used primarily to treat breast cancer, Herceptin had anti-proliferative effects on AD- and
AI-CaP xenografts when combined with the chemotherapeutic drug paclitaxel. Yeh et al.,
(1999) believe that Her-2/neu activated AR via the MAPK pathway, as inhibitors of MAPK
decreased HER-2/neu mediated activation of the AR. In effect, a positive feedback loop is
created where the AR can activate kinases and in turn, where kinases can activate the AR
through its phosphorylation (in the presence or absence of ligand), regardless of the varying
levels of androgens [1].
The AR pathway is thought to be in interplay with other signaling pathways. AR activation
due to cross regulation by receptor tyrosine kinases and their downstream effectors provides
alternative and sustained routes for AR activation despite androgen depletion. Currently,
there has been accumulating evidence that the phosphatidylinositol 3-kinase (PI3K)-AKT
pathway plays a significant role in CaP tumor progression. The cross-regulatory mechanism
by which the PI3K/Akt pathway modulates the expression and activity of AR is a novel area
of study. Growing evidence continues to support the increased role of the PI3K/Akt and AR
signaling pathways in mediating the progression of CaP to castrate resistant disease.
2. Phosphatidylinositol 3-kinase (PI3K)-AKT pathway: A brief overview
Evidence has largely supported the phosphatidylinositol 3-kinase (PI3K)-AKT signalling
pathway as a key regulatory system essential to mammalian cell proliferation, survival, and
metabolism. The gain- or loss-of-function of components of this pathway lead to neoplastic
transformation in a wide spectrum of human cancers, including CaP. Briefly, the canonical
PI3K/AKT pathway is activated by mitogenic growth factor stimulation of receptor tyrosine
kinases (RTKs), the most common RTKs include Epidermal Growth Factor Receptor (EGFR,
ERBB1), Her2 (EGFR-2, ERBB2), KIT, PDGFRα, and MET. Receptor activation causes RTKs to
dimerize and undergo autophosphorylation at tyrosine residues and enables interaction with
Src Homology 2 (SH2) domain-containing molecules. The signal then becomes transduced,
through the oncogene, RAS, and ultimately leads to the conversion of membrane phosphati‐
dylinositol-bis-phosphate (PI(3,4)P2; PIP2) to phosphatidylinositol-tri-phosphate (PI(3,4,5)P3;
PIP3) by PI3K. The presence of PIP3 mediates the recruitment of AKT (also known as PKB) to
the plasma membrane and its subsequent phosphorylation by 3-Phosphoinositide- Dependent
protein Kinase (PDK) 1 and PDK 2 at Threonine 308 (T308) and Serine 473 (S473), respectively.
Activated AKT or phosphorylated AKT (P-AKT) is the central effector of many downstream
signaling pathways regulating protein synthesis, cell cycle, cell death, cell growth, and cell
survival [summarized in Reference 82]. The loss and/or mutation of the tumor suppressor
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protein and negative regulator of the PI3K/AKT pathway, Phosphatase and Tensin homolog
deleted on chromosome TEN (PTEN), is a common event in various cancers, causing the
constitutive activation of PI3K/Akt signalling. PTEN, a dual protein and lipid phosphatase,
dephosphorylates PIP3 to PIP2, hence, buffering the proliferative and transformative effects of
the PI3K. This review will primarily focus on the most studied canonical PI3K/AKT pathway.
2.1. Phosphatidylinositol 3-kinases
The PI3Ks are enzymes that are grouped into three classes (I-III). Most members of this family
are bound to regulatory subunits which determine its specificty and function [83-85]. Class I
PI3Ks are subdivided into IA and IB and are members to the canonical PI3K/AKT pathway.
They are heterodimeric serine and threonine kinases comprising a catalytic subunit, p110, and
a regulatory subunit encoded by the PIK3CA and PIK3R1 genes, respectively [83]. The four
isoforms of p110 (α-δ) and their regulatory subunits have distinct structure-function domains
and specificity. For p110α, β, and δ the most commonly associated regulatory subunit has been
identified as p85 [83]. Specific isoforms of the p85 adaptor subunit (p85α, p85β, p50α, p55α,
or p55γ) facilitate the interaction with RTKs as well as the p110 catalytic domain isoforms [86].
The p85 subunit directly associates with active RTKs through the physical interaction of its
SRC homology 2 (SH2) domain at phosphotyrosine residues of RTKs [87]. The consensus
sequence has been identified to be YXXM [87]. In particular, Class IA PI3Ks’ p85α subunit
encodes an adaptor-like protein that has two SH2 domains and an inter-SH2 domain that binds
constitutively to the p110 catalytic subunit [87]. The two splice variants (p55α and p50α) retain
such regions but lack an amino terminal SH3 domain (mediates the binding of proline rich
sequences) and a breakpoint cluster region (BCR) homology domain (a protein-protein
interaction motif) [87]. The p110 isoforms (α, β, δ) have the same basic structure, including a
kinase domain and a C2 domain for membrane anchoring [87].
Class I PI3Ks, once activated by RTKs (Class IA) or G-protein-coupled receptors (GPCRs, [Class
IB]), have preferred substrates, in particular, the non-phosphorylated phosphatidylinositol
(PI), inositol monophosphate (PI(4)P), and phosphatidyl-bis-phosphate (PI(4,5)P2), and
mediate the addition of a phosphate group in the D-3 position of the inositol ring to generate
PI(3)P, PIP2, and PIP3, respectively [83, 88]. PIP3 is a potent second messenger in the cell and
the predominant arbitrator of PI3K signalling. Class IA PI3K p110α domain isoform is the most
mutated amongst cancers, causing the kinase to be more active [86, 89, 90] and perpetuating
a constitutively active PI3K pathway. Class II and III PI3Ks, on the other hand, are less studied
and are recognized for their involvement in membrane trafficking and receptor internalization,
and, vesicle trafficking, respectively [91-93]. PI3Ks within Class II generate PI(3,4)P2 from
PI(3)P and can also produce PI(3)P from PI. However, they cannot recognize PIP(4,5)P2 as
substrate to produce PIP and PIP2. Class II PI3Ks use only PI to convert it to PIP [83, 94].
Furthermore, unlike Class I PI3Ks, Class II PI3Ks do not require a regulatory subunit but
comprise three distinct isoforms to mediate their functions. Class IA PI3K will be discussed in
this review and will be referred to as PI3K unless otherwise stated.
PI3K activity is normally strictly regulated within the cell by growth factor-receptor interac‐
tions [95]. As such, the majority of the PI3K is inactive in the cytosplasm and remains removed
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from its plasma membrane substrates. Moreover, only a small fraction of these PI3Ks become
activated upon growth factor stimulation [95]. Currently, it is thought that there are pre-
formed inactive p85-p110 complex present in the cytoplasm, whereby ligand mediated
activation of kinase activity and transphosphorylation of RTK’s cytoplasmic tail recruits p85-
p110 complexes to the receptor by the SH2 domain of p85 [87]. This brings PI3K in close
proximity to its lipid substrates; moreover, it is reasoned that the RTK-p85 interaction may
remove an inhibitory effect of p85 on p110 kinase activity [87, 96]. This is thought to involve
conformational changes in the p85-p110 complex through the SH3 and BCR domains.
Mutations have now been identified in the genes coding for the p110 and p85 subunits which
have shed light on the pathology of metabolic diseases and cancer [83, 93].  These muta‐
tions occur at a frequency of 5-25% in common cancers such as breast, endometrium and
large intestine [83]. Activating mutations or ‘hot spots’ of PIK3CA occur at a frequency of
80% and are located in the PI3K catalytic kinase domain, H1074 and the helical domain, E542
and E545 [93]. Both mutations have been demonstrated to drive transformation in vitro [93,
97]. As a result, the lipid kinase activity is increased [83, 89, 98-102], downstream signalling
no long requires  upstream growth factor  stimulation,  and increased oncogenic  potency.
Expression  of  these  hot  spot  mutants  induced  oncogenic  transformation  in  avian  and
mammalian  cell  culture  and  transgenic  expression  of  H1047R  p110α  in  mouse  models
induced adenocarcinoma of the lung [83,  103].  As such,  hot spot mutations then can be
suggested to function as drivers of cellular transformation to a more oncogenic phenotype.
Conversely,  mutational inactivation of the ability of  p110α to interact  with RAS has the
opposite effect by decreasing the oncogenicity of helical domain mutants and minimizing
downstream signaling [83]. On the other hand, kinase domain mutants become independ‐
ent of RAS binding, and its oncogenicity is preserved [83]. PIK3R1 mutations occur within a
stretch of six residues (560-565) located in the inter-SH2 domain of p85 [83]. This area is the
contact point for p85 with the C2 domain of p110α whereby mutation leads to improper
binding to p110α and relieve the inhibitory interaction of p85 [83]. Enhanced AKT signal‐
ling,  stimulation of  cell  replication,  and oncogenic  transformation were some of  the ob‐
served effects [83, 104, 105]. As such, p85 mutations in the inter-SH2 domain can be thought
to be equivalent to activation mutations of the p110α C2 domain.
2.2. Phosphatase and tensin homolog deleted on chromosome TEN (PTEN)
The tumor suppressor, PTEN, is a dual phosphatase that has activity for both lipid and protein
substrates. It is a gene that is lost in both heritable and spontaneous cancers where germline
mutations cause autosomal dominant hamartoma tumor syndromes and where spontaneous
missense mutations occur frequently in the central nervous system (20%), endometrial (39%),
colorectal (9%), skin (17%), prostate (14%), and breast (6%) cancers [95]. Its role within the PI3K
pathway serves to negatively regulate PI3K signalling. PTEN functions to remove phosphates
in position 3' from phosphoinositides [93, 106, 107], therefore, returning PIP3 to PIP2 and
terminating the PI3K signal. Monoallelic loss (loss of heterozygosity) and/or mutation of PTEN
thus, leads to a hyperactive PI3K pathway to drastically impact tumor growth and disease
severity. PTEN mutants that retain protein tyrosine phosphatase activity but lose the ability
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to dephosphorylate PIP3 are found in many tumours indicating that PTEN lipid phosphatase
activity is required for tumour suppression.
PTEN is tightly regulated at the transcriptional level as well as by post translational modifi‐
cation, primarily through ubiquitylation. Incidentally, the levels of PTEN are controlled by
PI3K itself, through the regulation of the transcription factor NF-κB, while, PPARβ/δ agonists
and TNFα repress PTEN expression [93, 108]. Furthermore, the activity of PTEN is also
controlled by the PI3K pathway. In p85 conditional knockout mice, the loss of p85 resulted in
PTEN activity, while loss of p110δ isoform regulated PTEN activity through a RhoA-ROCK-
depedent signaling [93, 109]. Currently, NEDD4-1 is the first and only identified E3 ligase for
PTEN [93, 110]. Similar to PTEN, NEDD4-1 is also regulated by the PI3K pathway, thus
representing a positive feedback for PTEN degradation and PI3K activation [93, 111]. More
often than not, heterozygous alterations of PTEN are most common in the initial steps of
tumorigenesis. Surprisingly, complete PTEN deletion does not have pro-tumorigenic effect.
For example actute PTEN loss within prostate cells leads to a strong p53 dependent senescence
response that opposes cancer progression. Hence, it can be suggested that tumors may not
select for a complete loss of function of PTEN during the initial states of tumorigenesis. For
example, in CaP patients, approximately 70% of tumors have heterozygous alteration in PTEN
at presentaiton and then lose the other allele at later stages [93].
The co-existence of both PIK3CA mutations and PTEN loss has been observed in various
cancers. This suggests that these two genetic aberrations are not completely redundant and
may have additional selective advantage [95]. Yuan and Cantley, (2008) postulate that PTEN
and p110α exist in a negative feedback loop to regulate pathway activity, such that any
alterations to these enzymes results in heightened oncogenic potency of the PI3K pathway.
2.3. AKT/PKB
The formation of PIP3 is the central initiating event which functions to recruit plekstrin
homology (PH) domain containing proteins to the plasma membrane. Of relevance here, is
AKT/PKB, as it is the critical mediator of signal tranduction events downstream the PI3K
cascade. There are three members of the AKT family (AKT1, AKT2, and AKT3) and they are
broadly expressed to have some isoform specific features [87]. AKT1 is the major isoform
implicated in cancers, whereas AKT2 is more so involved in insulin signaling and glucose
transport. AKT3 on the other hand has well known features and functions, however is thought
to play a specific role in brain tissue [86, 112].
The AKT gene encodes a serine/threonine kinase with an amino-terminal PH domain, a central
catalytic domain, and a carboxyl-terminal regulatory domain. The regulation of AKT function
is two- fold, requiring its translocation to the plasma membrane and its sequential phosphor‐
ylation at Threonine 308 (T308) and Serine 473 (S473). Within unstimulated cells, AKT is
constitutively phosphorylated at S124 and T450. Upon PIP3 formation, there is direct interac‐
tion of AKT to PIP3 via is PH domain. Here, PDK1 phosphorylates AKT on T308. The phos‐
phorylation of T308 is a priming event to mediate the phosphorylation of S473 by PDK2, now
thought to be the mammalian target of rapamycin complex 2 (mTORC2). This secondary event
is necessary for maximal activation of the kinase, increasing AKT activity 10-fold [86, 113,
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114]. Once activated AKT has many substrates within the cytoplasm and nucleus, including
those that regulate apoptosis, proliferation, and protein translation. Although the activation
of AKT has been well established, there is little known regarding the dephosphorylation of
AKT as no AKT specific phosphatase has been identified. However heat-shock protein 90
(HSP90) has been demonstrated to protect AKT from dephosphorylation by the ubiquitous
phosphatase, PP2A.
The activation of AKT regulates many cellular processes including cell proliferation and
survival, cell size and glucose homeostasis, metabolism, angiogenesis, and tissue invasion [86,
93]. Amplification and mutations of AKT have been reported for pancreas, ovarian, head and
neck and breast cancers. This includes a recently identified missense mutation to the PH
domain of AKT1 (E17K) [95]. Such a mutation resulted in constitutive association of AKT with
the plasma membrane and its prolonged activation. The biological effects of AKT activation
relevant to cancer is primarily associated with cell survival, proliferation and growth. First,
AKT functions as an anti-apoptotic response to various stimuli. This is through a series of
phosphorylation and inhibition events of key pro-apoptotic proteins including, BAD, MDM2
and members of the Forkhead family of proteins.
BAD is a member Bcl-2 family of pro-apoptotic protein where these members form non-
function hetero-dimer complexes with the survival factor BCL-XL [87]. Once AKT phosphor‐
ylates BAD on S136, it prevents the interaction of BAD with BLC-XL to restore the anti-apoptotic
function of BCL-XL [86, 115]. AKT also phosphorylates the pro-death enzyme, caspase 9, and
inhibits its catalytic activity; this is in addition to preventing the nuclear localization of the
Forkhead family of transcription factor, FKHR which transcriptionally inhibits the expression
of pro-apoptotic proteins, BIM and FAS ligand. Alternatively, an indirect mechanism of AKT
regulation of apoptosis is mediated by the NF-κB pathway and p53. Specifically, phosphory‐
lation of and hence, the activation of IκB kinase (IκK) results in the degradation of NF-κB
inhibitor, IκB, causing the nuclear translocation of NF-κB and the expression of anti-apoptotic
genes. The pro-apoptotic effects of p53 tumour suppressor protein are mediated by AKT
phosphorylation of the p53 binding protein MDM2. MDM2 is a negative regulator of p53
function as it targets p53 for ubiquitin mediated proteosomal degradation through its E3
ubiquitin ligase activity. The phosphorylation of MDM2 increases the efficiency by which
MDM2 translocates to the nucleus thereby enhancing p53 degradation.
The proliferative effects of AKT activation can be attributed to its role by inactivating the cell
cycle inhibitor p27 and p21, and, by inhibiting the enzyme, glycogen synthase kinase (GSK)
3β at its Serine 9 phosphoryaltion site. The regulation of cell cycle progression is through cyclin-
cyclin-dependent kinase (CDK) complexes and CDK inhibitors (CKI). p27and p21 are CKIs
that become phosphorylated by AKT and through indirect mechanisms, AKT phosphorylation
can modulate the expression of CKIs as well as their activities. Phosphorylation of p27 renders
it inactive and promotes cell cycle entry. Additionally, phosphorylation of the transcription
factor, FOXO3A, by AKT causes the nuclear expulsion of the transcription factor, and therefore
decreases the expression of p27 [116]. Alongside CKIs, cyclin D1 levels are important for
G1/S phase transition through the cell cycle. AKT has an important role in preventing cyclin
D1 degradation by inhibiting the cyclin D1 kinase, GSK3β. This prevents the phosphorylation
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of cyclin D1 thereby increasing its levels to enable cell cycle progression. Interestingly, cyclin
D1 expression is also tightly controlled by FOXO3A. Upon AKT phosphorylation of FOXO, its
exclusion from the nucleus increases cyclin D1 expression. In effect, FOXO3A is considered a
transcriptional repressor for this gene.
The significance of AKT in cancer progression is further heightened by its role in cell growth
and metabolism. In highly proliferating tumor cells, there is rapid synthesis of macromolecules
to meet the biosynthetic demands required by the cell. Incidently, AKT is one of the main
regulators of protein translation and ribosome biogenesis [93], facilitating the means for cell
growth. This is primarily achieved through the serine/threonine kinase, mammalian target of
rapamycin (mTOR or FRAP1) Complex 1, which is composed of the protein kinase mTOR and
a series of interactors. This complex serves as a molecular sensor of nutrient availability and
in effect, modulates protein synthesis. It is unlikely that the PI3K/AKT pathway is the sole
simulator of mTOR activity. Nonetheless, AKT’s phosphorylation of two independent
substrates of this complex contributes to the oncogenic phenotype. Specifically, AKT phos‐
phorylates and inactivates the GTPase-activating protein (GAP) Tuberous Sclerosis Complex
(TSC) 2 which forms a complex with TSC1 to inhibit the GTPase, Ras-homolog enriched in
brain (Rheb). Rheb then directly interacts with mTOR and activates mTORC1 through the
inhibition of FKBP38, the negative regulator of mTORC1. Alternatively, the phosphorylation
and inhibition of another negative regulator of mTORC1, PRAS40 (proline-rich AKT substrate
of 40kDa), enhances the activity of mTORC1 through its competition with GTPase Rheb.
Altogether then, AKT promotes the activation of mTORC1 which initiates the translational
machinery to produce ribosomes and increase the rate of protein synthesis. REFS
2.4. Mammalian Target of Rapamycin (mTOR)
mTOR is a member of two distinct complexes, mTOR Complex 1 (mTORC1) and mTOR
Complex 2 (mTORC2) [83, 117]. It is thought that the mTORC1 complex plays a more dominant
role in tumor progression while the mTORC2 complex is more significant to mediating signals
to the cytoskeleton [116] and now identified as the factor responsible for the phosphorylation
of AKT at S473. This phosphorylation event maximizes the activity of AKT and opens its targets
to include PRAS40 and FOXO [83]. Moreover, it is another mechanism through which to
provide positive feedback on the PI3K pathway [86,113].
The mTORC1 pathway is a central point of signal integration for growth factor signalling,
energy state (AMP levels), and, nutrient and oxygen availability [118] which are fundamental
for regulating tumor cell growth. The particular interest for this pathway has been largely
determined by the discovery of the specific inhibitor, rapamycin, which blocks mTORC1
activity through yet unknown mechanisms. mTORC1 is comprised of Regulatory Associated
Protein of TOR (RAPTOR), LST8 and PRAS40 [83]. The complex itself has many substrates,
which upon its activation phosphorylates and activates S6 kinases (S6K) 1 and 2 (activation of
protein translation and ribosome biogenesis), as well as inactivates 4E binding protein (4EBP)
1, 4EBP2, 4EBP3, which releases the inhibition of eukaryotic intiation factor 4E (eIF4E). mTOR
dependent protein synthesis affects 5' untranslated polypyrimidine tracts of complex secon‐
dary mRNA structures. Such mRNA structures require eIF4A helicase activity together with
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eukaryotic initiation factors eIF4E and eIF4G to from the EIF4F initation complex. Altogether,
the main effect is to upregulated protein synthesis.
Although the PI3K/AKT pathway serves to activate the mTORC1 pathway, mTORC1 itself
negatively regulated the PI3K pathway. Over the years, studies have shown that mTORC1
inhibition can lead to PI3K activation. Moreover, mTOR activity can be suppressed by PI3K
inhibitors such as wortmannin and LY294002 [87]. However, it is unclear whether the mech‐
anism of activation of mTOR by AKT can completely drive tumorigenesis. As rapamycin can
inhibit AKT dependent cancers, it is presumed that in some part mTORC1 does have tumori‐
genic effects. Although there is correlation between increased translation and tumorigeneisis,
whether this is sufficient for increased cancer susceptibility is yet to be determined.
3. The PI3K/Akt signaling pathway and prostate cancer
In the recent years, emerging evidence has strongly linked the deregulation of the PI3K
pathway to prostate carcinogenesis and castrate resistance, although its precise role remains
elusive. Two components of this pathway, PTEN and PI3K, are currently the focus of intense
investigation and this section aims to address their role in the pathology of prostate cancer.
3.1. The incidence of genetic PTEN alteration
The deletions involving the chromosome 10q, which hosts the PTEN locus, 10q23, in CaP is a
frequently observed phenomenon. Modifications to PTEN in various stages of CaP have been
characterized to include both homozygous and hemizygous deletions, as well as inactivating
mutations. Although the incidence and the modes of these alterations have been inconsistent
across studies, the severity of PTEN loss seems to correlate with disease progression [119].
Whereas locally confined CaP presents homozygous deletions of PTEN ranging from 0% to
15%, the incidence within metastases can increase up to 30%. Likewise, heterozygosity loss
occurs in 13% of the locally confined cases and up to 39% in metastatic phenotypes [120].
Further support has comefrom interphase fluorescence in situ hybridization (FISH) analysis
of histologic sections, which reported genomic deletion of PTEN in 23% of high-grade intra-
epithelial neoplasia (HGPIN) and 68% of prostate tumors [121]. Recently, Han et al., (2009)
demonstrated that PTEN deletion occurs in 9% of premalignant prostate, a proportion which
increases to 17% in localized CaP and to 54% when metastasized. Functional loss of PTEN can
also be generated through point mutations, which are seen in upwards of 16% of primary
tumor and 20% to 30% in advanced stages [120]. Taken together, these studies suggest the
deletion of PTEN is likely a late genetic occurrence in CaP progression.
3.1.1. Mechanism of PTEN loss
Although the incidence PTEN alterations in CaP have been extensively characterized in the
past ten years, the mechanism by which genomic PTEN deletions occur remains to be eluci‐
dated. The high frequency of large-scale chromosomal events leading to the loss of PTEN locus
suggests unique features that may enhance DNA rearrangements at 10q23. Yoshimoto et al.,
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(2012) identified recombination hotspots known as segmental duplications (SD) 17 and 18 to
be located between PTEN and BMPR1A. The SDs are typically part of a 1-400 kB genomic
region exhibiting over 90% homology [123, 124] responsible for improving the likelihood of
constitutional microdeletion events [125]. Utilizing meta-analysis of published prostate cancer
genomes to map 10q23 deletion sites and FISH for confirmation, Yoshimoto et al., (2012)
demonstrates SD17-SD18 colocalizes with a deletion breakpoint hotspot occurring in 69% of
PTEN losses, which suggests SD17 and SD18 facilitate homology-dependent rearrangements
of DNA that lead to a PTEN deletion breakpoint. The presence of these SDs thus destabilizes
the genome, predisposing CaP progenitors to genomic microdeletions that ultimately result
in PTEN loss. Subsequent attenuated PTEN expression has been shown to further diminish
genomic stability [126], leading to the acquirement of other chromosomal abnormalities [127].
Cells bearing homozygous PTEN deletion would have significant stronger growth advantage
and predominate due a constitutively activation of the PI3K pathway. This sequence of events
may explain the progressive loss of PTEN as prostate turmorigenesis continues.
3.1.2. The clinical and cellular impact of PTEN loss
The functional loss of PTEN in CaP has been shown by numerous studies to confer poor
clinical prognosis and predict disease progression. Genomic PTEN deletions studied through
either immunohistochemistry or FISH have been correlated with increased Akt phosphoryla‐
tion, higher Gleason grade, biochemical relapse, angiogenesis, and larger tumor sizes [123,
128-132]. Specifically, Yoshimoto et al., (2007) demonstrated that haploinsufficiency of PTEN
is  associated  with  an  earlier  onset  of  biochemical  relapse  after  prostatectomy  while  bi-
allelic deletion of PTEN is associated with an even shorter time to relapse. Additionally, loss
of PTEN near the time of prostatectomy correlated strongly with extraprostatic extension and
seminal vesicle invasion.
Decreased expression of PTEN profiled by high-density tissue microarray was shown to also
increase the risk of tumor recurrence after radical prostatectomy [129]. Similar findings were
reached in immunohistochemical evaluation of PTEN expression in CaP glands. Using a nested
case-control study, the group Chaux et al., (2012) found patients with reduced PTEN expres‐
sion was at a higher risk of relapse, independent of identified clinicopathological covariates.
Their previous study also linked attenuated PTEN levels to faster onset of metastasis in CaP
patients [134]. Additionally, the use of transgenic mouse models have served to recapitulate
features of PTEN loss in humans and concomitantly fostered a greater understanding of the
PI3K pathway alongside clinical studies. Prostate specific PTEN-/- null knockout mice proceeds
linearly from acquiring prostatic intraepithelial neoplasia (PIN) to adenocarcinoma to meta‐
stasis, mimicking the disease progression in human CaP [135]. The prostate tumors also
exhibited temporary regression following androgen ablation, but eventually proliferated
androgen independently. Further, mice with one deactivated PTEN allele combined with
p27KIP1 loss exhibit accelerated spontaneous neoplastic transformation and tumorigenesis
[136]. These studies of mouse and human prostate cancers combine to emphasize haploinsuf‐
ficiency of PTEN as a key predictor of disease states in prostate cancer.
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3.2. The role of PI3K isoforms
The catalytic isoform p110β and its regulatory complex p85α have been shown to mediate AR
transactivation in the presence of androgens [137]. Overexpression of wild type p110β led to
androgen-independent AR transactivation while the overexpression of p110α gene showed
no effects. Interestingly, short interference RNA (siRNA) disruption of p110β gene in prostate
cancer cells abrogated tumor progression in vivo. Moreover, clinical analysis of tumor samples
linked high p110β and p85α expression at the mRNA and protein level to malignant prostate
tumors, metastasis and poor differentiation.
Conditional knockout mouse models of p110β have further provided insight into the onco‐
genic potential of the catalytic subunit. Prostate epithelium remained normal in the absence
p110β alone while PTEN loss alone resulted in tumor growth in the anterior lobe by 12 weeks;
subsequent ablation of the p110β gene rescued PTEN null anterior prostate from tumorigenesis
[138]. Increased phosphorylation of Akt on Ser473 was achieved through PTEN loss while
additional ablation of p110β attenuated Akt activation. These results are not attributable to
changes in the p110α subunit as minimal changes in tumor growth and Akt phosphorylation
were observed upon p110α ablation. One study ascribed the differential functions of the
p110α and p110β catalytic subunits to the distinct pools of PIP3 they generate [139]. The
p110α, in response to growth factor stimuli, will cause an immediate flux of PIP3 coupled with
efficient Akt phosphorylation, whereas p110β will maintain a basal level of PIP3 with minimal
effects on Akt phosphorylation. Together with the observation that p110β-specific inhibitors
effectively reduce Akt phosphorylation in the absence of PTEN in vitro [139], oncogenic
transformation of prostate cancer cells upon PTEN loss is likely derived from the p110β-
catalyzed pool of PIP3 [138]. These data collectively support distinct functionalities of the
p110α and p110β catalytic subunits in PI3K/AKT signaling.
Recent studies have also shed light onto the third isoform of PI3K catalytic subunit, p110δ.
Tzenaki et al., (2012) reported CaP cells that contain high levels of p110δ activity have
dampened PTEN functionality. Treatment with p110δ -specific inhibitor in DU145 cells
promoted PTEN activation, reduced Akt phosphorylation and inhibited cell proliferation. In
another cell line (22Rv1) with wild-type PTEN and low p110δ expression, measured basal
PTEN activity was comparatively higher than that in DU145 cells. Inhibition of p110δ in 22Rv1
likewise did not affect Akt phosphorylation status or cell proliferative abilities. Hence, the
development of p110δ -selective inhibitors may hold promise since blocking p110δ activity
will also indirectly inhibit other catalytic isoforms through PTEN activation.
4. PI3K/AKT and AR Signalling axis
The role of the PI3K/AKT pathway in CaP cell proliferation, survival and progression from
AD to AI disease has been linked to androgen receptor (AR) transcriptional activity, stability
and expression. This section of the review will discuss the various modes of crosstalk between
the PI3K-Akt and AR axis.
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4.1. PI3K/PTEN and AR
The activation of Akt has provided a mechanistic link between PI3K and AR transactivation.
However, other modes of interaction have been shown. AR can directly interact with the p85
regulatory subunit of PI3K. Upon their binding, the AR enhances PI3K enzyme activity to
ultimately upregulate Akt phosphorylation [141]. Conversely, EGFR stimulated PI3K activity
was decreased in PC-3 cells transfected with wildtype AR relative to AR null PC-3 cell line
[141-142]. PI3K activity was further reduced upon R1881 treatment, suggesting AR activation
as a negative regulator of PI3K stimulation. The role of androgens within the AR-PI3K axis has
also shown their significance in modulating cell proliferation and growth. Multiple reports
have demonstrated that androgens enhance PI3K activity and increase downstream Akt
phosphorylation. In NIH3T3 fibroblasts, there was rapid activation of the PI3K/AKT pathway
upon androgen stimulation. While this required the presence of the AR, AR transactivation
was not essential [141, 143]. Low concentration of androgen further stimulated the association
of the AR with Src and PI3K, which triggered the cells into S-phase entry [141, 143].
The negative regulator of the PI3K pathway, the PTEN tumor suppressor gene, as discussed
previous is frequently inactivated in CaP as well as in CaP cell lines which include PC-3 and
LNCaP. Functional loss of PTEN is associated with increased AKT phosphorylation, higher
Gleason score, and poor prognosis [120, 144]. The development of conditional mouse models
of PTEN -/- has shown that PTEN alone can drive the progression of CaP through invasion,
metastasis and AI proliferation [82]. Although there was heightened PI3K activity, there was
continued evidence of AR gain-of-function despite reduced steroid ligand levels [45, 82]. For
example, prostatic epithelium in PTEN-/- mice was still sensitive to androgen withdrawal. As
such, Mullholland et al., (2006) suggest that while the AR remains functional and sensitive to
androgens, the PI3K/AKT and AR oncogenic signaling may complement and compensate for
one another during the time of androgen ablation therapy. This is supported by studies
demonstrating cells lacking PTEN had elevated PI3K/AKT axis activity upon androgen
withdrawal [45, 46, 82]. Hence, PTEN loss may allow for epithelium with sufficient PI3K/AKT
signaling to maintain cell proliferation and promote AR gain of function [82].
Currently, there is no direct method that supports PTEN loss for promoting AR-specific gene
activation. However, CaP xenograft studies have shown that amplification of AR does occur
[82, 147] under a PTEN null background, which can be correlated to increased AR stabilization
[82]. Li et al, (2001) demonstrated that PTEN itself can negatively regulate AR gene targets
such as PSA, reduce the nuclear localization of the AR and promote receptor degradation
through caspase 3 or the proteosome [82]. Alternative to AR amplification and stabilization,
the loss of PTEN may also contribute to AR activation through the various coregulators of the
AR, this includes ARA70 [149] and ARA54 [150]. Such regulation by PTEN would allow for
heightened AR response to low androgen concentrations or responsiveness to non-androgen
ligands. On the other hand, at low androgen levels, AR expression alone can also stimulate
cell proliferation (Denmeade et al., 1996) while PTEN restoration induced apoptosis and
growth arrest [151]. However, in the presence of androgens, PTEN expression was sufficient
to reduce cell proliferation but not induce apoptotic response [82, 148, 152]. PTEN loss then,
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results in an indirect AR gain-of-function phenotype by establishing an environment that may
increase AR oncogenicity and CaP metastatic potential.
4.2. AKT and AR cross-talk
The regulation of the AR by Akt through direct and indirect modes of interactions has been
demonstrated in literature. These include, but not limited to 1) direct phosphorylation of the
AR by AKT, 2) AKT/mTOR dependent regulation of the AR, 3) AR interaction with FOXO
family of transcription factors downstream AKT, and 4) AR regulation by AKT via the Wnt/
GSK3β/β-catenin cross-talk.
4.2.1. AKT and direct AR phosphorylation
AKT binds to the AR to directly phosphorylate at AR consensus sites, S213 and S791. Upon
phosphorylation by AKT, the AR becomes transcriptionally active under physiological
androgen concentrations. However, a study Xin et al, (2006) demonstrated that AR phosphor‐
ylations at S213 and S791 were not critical for tumor progression, which indicated that AR
phosphorylation may not be the sole regulatory event inducing AR transcriptional activity
[153, 141]. Alternatively, at high androgen concentrations, AKT can protect CaP cells from
apoptosis and suppress AR transcriptional activity by phosphorylation at S210 and S790 [49].
Lin et al, (2002) also demonstrated that AR phosphorylation by AKT resulted in MDM2
mediated ubiquitlyation of the AR, leading to its proteosomal degradation. Taken together,
these data indicate AKT-mediated regulation of AR activity is dependent on the external
environment.
4.2.2. PI-3K/AKT/mTOR and AR
A potent nutrient and growth/survival pathway kinase, mTOR has been implicated in the
progression of several types of cancer. Interestingly, it has been identified as a regulator of AI-
CaP growth, but not CaP growth, by Ghosh et al. (2005). Further, it has been implicated in
regulating the progression to androgen-independent disease [155-156] alongside AR signaling.
There are three key routes through which mTOR could potentially interact with AR signaling:
through its kinase activity as mTORC1 or mTORC2, post-transcriptional regulation via
regulation of translation factors, or indirectly through a signaling cascade. Several broad
studies have implicated a connection between the two molecules. Sircar et al. (2009) showed
that AKT activation, mTOR activity and AR nuclear expression concurrently occur in several
PTEN-null patient samples. Additionally, Müller et al. (2012) demonstrated that loss of
phosphorylation of Ser2448 of mTOR, an inhibitory alteration, resulted in decreased levels of
cellular AR in ERG-fusion-positive prostate cancer cells. Kaarbø et al. (2010) also show a
reduction of AR by mTOR in LNCaP cells. Furthermore, they demonstrate that mTOR
inhibtion increases ligand-dependent AR activity.
Work by Wang et al. (2008) further demonstrated evidence of a connection between mTORC1
signaling and AR by demonstrating an induction of AR activity by rapamycin. The application
of rapamycin to LNCaP and C4-2 cells resulted in inhibition of the mTORC1 pathway, but an
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increase in AR transcriptional activity. They further determined that this relationship was
through AKT. Inhibition of mTORC1 by rapamycin was shown to activate a parallel AR-
mediated survival pathway putatively downstream of mTORC2. This potentially matches
results by Müller et al. (2012), who showed that loss of mTOR deactivation resulted in AR
reduction, suggesting an inverse relationship between the two molecules. Upon dual inhibition
using rapamycin and bicalutamide, apoptosis occurred [159], signifying that there is a parallel
compensatory effect for mTORC1 signaling through AR. This relationship was expanded on
by Wu et al., (2010) who determined that the relationship between AR and mTORC1 is
dependent upon testosterone availability, and generates a self perpetuating cycle that pro‐
motes cell survival. In low testosterone conditions, application of bicalutamide repressed
mTOR activity, as did siRNA against AR in both low and high testosterone conditions. This
was shown to be through AR repression of TSC2, a negative regulator of mTORC1. Conversely,
rapamycin treatment induced AR activity, as was previously shown by Wang et al. (2008).
Furthermore, in low testosterone conditions, where AR activity is low and thus TSC2 is not
repressed, bicalutamide leads to apoptosis [160].
These data support the compensatory AR-mediated growth pathway found by Wang et al.
(2008), as the lack of TSC2 repression would inhibit mTOR signaling while bicalutimide
inhibits AR, leading to a similar dual inhibition of mTORC1 and AR which Wang et al. (2008)
reported to induce apoptosis. The interactions between mTOR and AR have been shown to
play a key role in progression to AICaP. The mechanism elucidated by Wu et al. (2010)
demonstrated that LNCaP cells can become attuned to low testoterone by mTOR/AR crosstalk.
When testosterone is low, AR activity drops, but so then does AR-mediated inhibition of TSC2.
This represses mTOR activity, leading to induction of AR activity once more. If this cycle is
perpetuated, the cells will become able to self-induce AR signaling, and thus also reestablish
mTORC1 activity, leading to the development of an androgen-resistant and highly prolifera‐
tive tumor. Additionally, LNCaP cells acclimatized to low-testosterone conditions showed
resistance to glucose deprivation, another way of repressing mTOR. The mTORC1 repression
leads to higher levels of AR transactivity, activating a postulated second survival pathway that
can compensate for the canonical PI-3K/AKT/mTOR axis. Thus, inhibition of one pathway
would sensitize to inhibition of the other. Only by inhibition of both mTOR and AR was
apoptosis achieved in both studies [159, 160]. Squillace et al. (2012) show similar results using
bicalutamide and ridaforolimus, an mTOR inhibitor. In their study, they [161] also demon‐
strate that the combination therapy does not induce apoptosis in healthy RWPE-1 PTEN-
expressing prostate cells. This is important, as it indicates that the targeted AR/mTOR system
is an aberrancy in the tumour.
AR/mTOR dual inhibition was shown to be key to regulation of CaP progression by Schayo‐
witz et al. (2010), who demonstrated that usage thereof can prolong androgen sensitivity of a
tumour. Using mouse models, Schayowitz et al. (2010) showed that combination therapy had
significant effect on both xenografted androgen-dependent (LNCaP) and androgen-independ‐
ent (HP-LNCaP) tumours. In both LNCaP and HP-LNCaP xenografts, treatment with a single
inhibitor caused no significant decrease in tumour volume, while combination therapy
reduced tumour volume significantly. Bicalutamide or everolimus (an mTOR inhibitor) did
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not decrease tumour volume in LNCaP xenografts, while combination treatment offered
significant reduction after 15 days [162]. Likewise, in HP-LNCaP xenografts bicalutamide,
everolimus or VN124-1 (a novel androgen/AR inhibitor) did not significantly decrease tumour
volume, while dual inhibition did. Interestingly, combination everolimus/VN124-1 treatment
reduced tumour volume far more than did everolimus/bicalutamide treatment. Everolimus/
VN124-1 treatment also resulted in significant decreases in AR, p-mTOR, p-S6K and p-S6 levels
as visualized by western blotting [162], signifying an inhibition of the AR/mTOR pathways.
Single inhibition often led to increased pathway activation, further evidencing compensatory
crosstalk. This study is notable because treatment of xenografts with the combination treat‐
ment was not overcome, nor was its efficacy as compared to tumour volume decreased over
a 45-day period. This indicates that sensitivity to the dual inhibition was maintained, and
compensatory crosstalk did not rescue the xenograft. Suppression of CaP progression to AI
disease in this manner was also shown by Friedrichs et al. (2011), albeit through a different
treatment. Omega-3 polyunsaturated fatty acids (PUFAs) were shown to inhibit CaP progres‐
sion through suppression of mTOR and AR signalling. Application of DHA, an omega-3 PUFA,
inhibited AKT signaling and decreased cell growth in AI clones of LNCaP. Friedrichs et al.
(2011) also observed the effect of omega-3 PUFAs on suppression of CaP progression using an
assay that mimics progression to androgen-independent disease with androgen ablation. In
the control group, ~35% of the cells initally underwent growth arrest and then recovered, while
~42.5% stayed arrested. In the omega-3 PUFA groups (+DHA, +EPA), a majority of cells stayed
arrested, as did cells treated with an AKT inhibitor. Treatment with DHA was also accompa‐
nied by suppression of AR and p-mTOR expression, along with downregulation of p-S6 and
of p-TSC2, an AKT target. This data taken together with data by Wang et al. (2008), Wu et al.
(2010), Schayowitz et al. (2011) and Squillace et al. (2012) suggest that suppression of both
mTOR and AR signaling is key to inhibition of CaP progression, and that single inhibition
leads to activation of the other in a compensatory mechanism.
Such a mechanism was postulated by Wang et al. (2008) to be downstream of mTORC2.
Facompre et al., (2012) report that that mTORC2 is involved in an AR-mediated growth
pathway. Addition of 5μM p-XSC, or 1,4-phenylenebis(methylene)selenocyanate, a known
AKT and AR inhibitor, was shown by Facompre et al. (2012) to inhibit mTORC2 kinase activity
in vitro, supporting Wang et al. (2008) in proposing that mTORC2 plays a role in AR-mediated
crosstalk. This dual inhibition of AR and mTORC2 could indicate that either p-XSC is an
mTORC2 inhibitor and inhibits AR downstream of TORC2, or that AR is upstream of mTORC2
and thus suppression of AR inhibits mTORC2 signaling. Treatment with p-XSC resulted in
decreased growth of both androgen-dependent LNCaP and androgen-independent C4-2 CaP
cell lines by ~25%, with rapamycin showing similar results [163]. As indicated by several other
sources, dual inhibition had a far more marked effect. Addition of 1nM rapamycin in combi‐
nation with the mTORC2/AR inhibitor p-XSC heavily decreased cell viability by ~50% in
LNCaP calls, and by ~60% in C4-2 cells. The dual inhibitor treatment resulted in extremely
efficient repression of phosphorylation downstream of both mTOR complexes, further
supporting the postulation that an AR survival pathway is related to mTORC2. The role of
mTORC2 in AR signaling has been investigated by Fang et al. (2011), who report that an
mTORC2-mediated growth pathway is downstream of AR. Treatment of CWR22R3 cells with
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DHT led to proteosome-mediated degradation of p27, a protein that induces cell cycle arrest
through CDK inhibition. Such an action would contribute to the inhibited growth noted in CaP
progression. This degradation was shown to be through mTORC2-mediated phosphorylation
of AKT at Ser473, but not Thr308. AKT has previously been shown to be phosphorylated at
Thr308 by PDK1 [165], so the modification of AKT in this context seems to be purely mediated
by mTORC2 without influence from PDK1 molecules, leading to selective activation of only
certain downstream substrates, such as SGK and PKCa. Fang et al. (2011) went on to demon‐
strate that DHT stimulation of AR is inducing nuclear accumulation of SIN1, a factor required
for complexing of mTORC2, which signals for the assembly of mTORC2 and subsequent partial
phophorylation of AKT. The actual phosphorylation of p27, required for its degradation, could
be mediated by AKT or one of its selectively activated substrates. Growth pathways down‐
stream of AKT, such as the SGK pathway, would also lead to increased viability and prolifer‐
ation of CaP. Xu et al. (2006) implicated mTOR in a similar manner, showing that AR induces
cyclin proteins, especially cyclin D1, D2 and D3. RT-PCR results did not indicate a similar
increase at an mRNA level. This was because AR regulation of cyclin D was at a post-tran‐
scriptional level, through mTOR. Co-activation of cyclin proteins together with degradation
of p27, a CDK inhibitor, could lead to potent activation of a CDK-Cyclin growth pathway.
AR has also been shown to be post-transcriptionally modified by mTOR [167] in an EGF/PI-3K/
AKT-dependent manner. This study elucidates the manner in which mTORC1 regulates and
rapamycin induces AR. Through modulation of the interactions between translation initiation
factor eIF4E and scaffolding protein eIF4G, mTOR putatively regulates the rate of translation
of AR. Thus, rapamycin inhibition of mTORC1 would lead to an increased rate of translation
of AR, leading to increased expression and revitalization of mTORC1 signaling. This combined
pathway contains a failsafe in the form of the mTOR-mediated repression of AR and the AR
regulation of TSC2, leading to cyclic and self-perpetuating support of two growth pathways.
This pathway has consistently been implicated as important to CaP survival, growth and
progression to AICaP. The data suggests that this crosstalk leads to maintainance of parallel
mTORC1 and mTORC2 survival pathways. The pathway is protected from itself: induction of
mTOR signaling decreases AR activity, which would enhance TSC2 and thus return mTORC1
to normal levels, rescuing AR. Repression of mTORC1 induces AR through attenuation of its
post-transcriptional inhibition, leading to downstream mTORC2/CDK-Cyclin signaling.
Additionally, AR represses TSC2, revitalizing the mTORC1 pathway. Repression of AR
increases TSC2 activity, leading to inhibited mTORC1 and thus increased AR, hypersensitizing
the cell and possibly leading to progression towards AI disease.
4.2.3. PI-3K/AKT/FOXO and AR
FOXO, a family of apoptosis-promtoing transcription factor, has shown relevance to AR and
prostate cancer progression. AR has previously been shown to be a positive regulator of the
PI-3K pathway, which represses FOXO family transactivity. Additionally, tissue microarray
data from TM3-AR CaP cells treated with testosterone display marked downregulation of 65
FOXO-family proteins [168]. Sixteen of these have been shown to be important in development,
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including FOXO1. These data suggest that AR and FOXO are antagonistic towards one another.
Li et al. (2001) first indicated an antagonistic nature of AR and PTEN/FOXO.
Ma et al. (2008) characterized one side of this antagonism, showing that FOXO1 mediates PTEN
inhibition of AR. By expressing fragments of FOXO1 and determining their ability to repress
AR activity, they discerned that the FOXO1 inhibition of AR required its AD and forkhead
box. Further, the inhibition of AR was found to be through disruption of its NTD/CTD
interaction. This disruption was found to be mediated by FOXO1 binding the AR NTD and
repressing interaction with SRC1, a promoter of AR activity [169]. Completing the dichotomy,
Li et al. (2003) showed that AR can also disrupt the activity of FOXO-family transcription
factors, including FKHR. Androgen treatment and subsequent AR activation in PTEN-null
cells was shown to repress FKHR and related FOXO-family protein activity in a manner
independent of transcriptional coactivators. This repression was found to be by complexing
of activated AR and FKHR, leading to an inability of FKHR to bind DNA. Two points of
interaction were found for each molecule: AR binds to the FKHR C-terminus and binds weakly
to the forkhead domain, while FKHR binds to the AR NTD and weakly to the LBD. Through
flow cytometry, Li et al. (2003) demonstrated that FKHR when bound by AR can no longer
induce cell cycle arrest, thereby leading to an attenuation of its role in growth control. This
suggests that androgen ablation therapy might reintroduce FKHR and related FOXO activity,
leading to arrest of cell growth. Thus, the progression to androgen independence would
require compensation for androgen deprivation, such as those discussed earlier. In particular,
mTOR and FOXO seem to have related roles. AR inhibition of FOXO combined with mTOR-
mediated growth signaling could lead to potent CaP proliferation. Additionally, mTOR-
related crosstalk could rescue FOXO-mediated AR inhibition.
Another similarity between FOXO and mTOR crosstalk with AR is the role of p27. Unlike
FOXO1 and FKHR, FOXO3a has been shown to transcriptionally upregulate AR by binding
its promoter [171], while AR deactivates FOXO3a [172]. FOXO3a also promotes transcription
of p27 via its promoter [173]. These interactions lead to a system where AR deactivates
FOXO3a, leading to inhibition of p27. If AR were reduced, FOXO3a would become active,
promote AR expression and thus reinstate the same state. Disruption of this cycle was shown
by Li et al. (2007), using a DIM compound called B-DIM. Treatment with B-DIM repressed
FOXO3a binding to the AR promoter while maintaining its binding to the p27 promoter,
leading to cell cycle arrest. In CaP, redundant repression by mTOR might prevent this method
of rescue. Additionally, AR disruption of FOXO proteins in conjunction with AR/mTOR
crosstalk would lead to a deadly regulatory loop whereby cell cycle regulation is suppressed
and growth is promoted. Zhang et al. (2010) also showed potential for FOXO-based therapy
in response to AR signaling. Methylseleninic acid (MSA) can be metabolized to methylselenol,
which has been shown to have anticancer effects and to induce apoptosis [175]. Zhang et al
(2010) found that treatment of LNCaP cells with MSA leads to induction of FOXO1 expression
and transactivity. Additionally, knock down of FOXO1 after MSA treatment was found to
nullify its apoptotic effects. The critical role of FOXO1 in this context was found to be repression
of AR activity, though the mechanism for this inhibition remains unknown. Based on results
from Ma et al. (2008), FOXO1 could be attenuating NTD/CTD interactions of AR. Results from
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treatments with FOXO-associated drugs such as B-DIM and MSA implicate it as an important
molecule in AR-mediated CaP growth and its role as an antagonist of AR could potentially
implicate it in CaP progression. Since AR/FOXO crosstalk is seemingly similar but opposite to
AR/mTOR crosstalk, investigation of both AKT-dependent and AKT-independent crosstalk
between the two pathways could elucidate important mechanisms of CaP progression.
4.2.4. PI-3K/AKT/GSK3β and AR
The evidence thus far clearly shows that increased activation of the PI-3K/AKT signaling
pathway and transcriptional activity of AR are closely intertwined. The role that AKT plays
in modulating AR activity, however, remains obscure. One of the many downstream substrates
of AKT, GSK3β has also been shown to play a role in AR regulation [176-179], and is ubiqui‐
tously expressed in CaP cell lines, including COS-1, PC-3, LNCaP and DU145 (Wang et al.,
2004). It has increased expression in AICaP cell lines [176, 179], and appears to be a key player
in the progression of CaP to androgen-independent disease. However, the nature of this role
is at present ambiguous. In varied contexts, GSK3β has been shown to both promote and
antagonize AR transactivaton independently of its interactors and other substrates in both a
ligand-dependent and ligand-independent manner.
A repressor of several EMT pathways, GSK3β has been shown by Salas et al. (2004) to be
capable of repressing ligand-dependent AR activity by phosphorylation. Transfection of wild
type GSK3β or constitutively active GSK-3ΒΔ9, a mutant of GSK3β devoid of its first 9 amino
acids, into AR-expressing LNCaP, A103 and V28 cells significantly increased phosphorylated
AR compared to transfection of empty pCMV4 or inactivated tyrosine 216 mutated GSK3β
(GSK3βY216F). Furthermore, treatment of cells with LiCl, a GSK3β inhibitor, significantly
decreased phosphorylation of AR (Salas et al., 2004), indicating that altered modification of
AR is indeed due to the activity of GSK3β. In AR- COS-1 prostate cancer cells, co-transfection
of wtGSK3β or GSK3βΔ9 with AR lead to increased phosphorylation of AR, as opposed to
cotransfection of AR with empty pCMV4 or GSK3βY216F which did not elevate phosphorylation
of AR. This suggests that the activity of GSK3β is essential to the phosphorylation of AR, as
the active forms of GSK3β were the only ones to display an effect. Upon treatment of AR-
expressing COS-1 cells with LY294002, phosphorylation of AR increased [176]. This is due to
reduced deactivation of endogenous GSK3β through indirect inhibition of AKT via the PI3K
pathway. When these cells were treated with LiCl, AR phosphorylation decreased in a dose-
dependent manner, indicating that these results are related to increased GSK3β activity. In
following with the increased phosphorylation of AR, Salas et al. (2004) also reported that AR-
mediated transactivation in the presence of R1881 (metribolone), a synthetic nonmetabolizable
androgen, was decreased with increased GSK3β activity. This was shown through luciferase
reporter assays both with an ARE-driven ARE2LUC construct as well as with a PB-LUC (a
promoter from an endogenous AR target). By using C-terminal and N-terminal domain
mutants of AR, Salas et al. (2004) were able to determine that GSK3β preferentially phosphor‐
ylates AR on its CTD. Furthermore, usage of a GST-tagged ARLBD revealed that GSK3β could
phosphorylate AR on its LBD. This may provide a mechanism by which AR-driven transcrip‐
tion is decreased by GSK-3β. The effect of GSK3β being through the AR LBD is further
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evidenced by the fact that Salas et al. (2004) did not note any suppression of the ligand-
independent, constitutively active AR5 and AR104 constructs.
Wang et al. (2004) also showed a reductive effect of GSK3β on AR transcription. Co-transfection
of AR, wtGSK3β and two reporter constructs in a dual luciferase system with an ARE-driven
promoter (ARE4) revealed that increased GSK3β decreased AR transactivation. Further, usage
of a constitutively active GSK3β mutant (GSK3βS9A) further restricted AR-driven transcription.
These data taken together suggest that GSK3β kinase activity regulates the level of AR
transactivation. GSK3β was also shown to decrease AR transcription in LNCaP cells, which
express endogenous AR. These effects were shown to be reversible by LiCl treatment. How‐
ever, in contrast to the work by Salas et al. (2004), Wang et al. (2004) demonstrated that
GSK3β phosphorylates AR on its NTD more significantly than its LBD or a DBD-LBD fragment
by using GST-tagged fragments. Moreover, they showed that GSK3β repressed transcription
by GAL4-AR-N-terminal in the presence of a pG5-Luc reporter, which contains the ligand-
independent AF-1 domain, while failing to repress activity of the AF-2 domain-containing
GAL4-AR-LBD. These data suggest that GSK3β inhibits ligand-independent activity of AR.
Wang et al. (2004) also demonstrated that GSK3β binds to the CTD and NTD of AR in both
transfected and endogenously expressing CaP cell lines, leading to the postulation that
GSK3β-mediated suppression of AR transcription may be due to attenuated AR CTD-NTD
interactions, which are required for transactivation. Supporting the interaction of the two
molecules, Salas et al. (2004) noted that there was a physical co-distribution of the two
molecules in CaP cell lines and in CaP tissue. Salas et al, (2004) reported that inhibition of
GSK3β by Ser9 phosphorylation is elevated in the androgen-dependent LNCaP in comparison
to the androgen-independent PC3 and DU145 CaP lines, which may signify an increased role
for GSK3β in androgen-dependent tumours. Liao et al (2004) also show that GSK3β Tyr216
phosphorylation is elevated in AICaP cells, especially 22-RV1. Aberrant activity of the
PI-3KAKT signaling system has been demonstrated in AI 22-RV1 CaP cells, and has been
associated with an increased Gleason grade [82], which in turn has been shown to be an
accurate predictor of progression to AICaP [182]. These data taken together suggest that the
increased activity of PI-3K/AKT in AICaP, usually due to PTEN deficiency, may have the effect
of disabling GSK3β and thus increasing activity of AR in a ligand-independent manner.
Work by Liao et al. (2004), Mazor et al. (2004) and Schütz et al. (2011) contradicts Salas et al.
(2004) and Wang et al. (2004), reporting that inhibition of GSK3β actually represses AR-
mediated transcription. Mazor et al. (2004) reported that GSK3β sequestration or knockdown
inhibits AR signaling, while transfection of a constitutively active form (GSK3βS9A) into LNCaP
cells with majority Ser9-phosphorylated GSK3β increased AR transcriptional activity. More‐
over, this effect was independent of its downstream substrate, the oncogenic β-catenin. Liao
et al. (2004) demonstrate that GSK3β is necessary for ligand-dependent transcriptional activity
to occur. In the presence of LiCl, two other GSK3β inhibitors RO318220 and GF109203X and
siRNA against GSK3β, R1881-stimulated AR transcriptional activity as measured by a PSA-
SEAP reporter was significantly reduced. This was not due to reduced nuclear translocation,
as no inhibitors blocked AR nuclear localization with R1881 treatment. Knockdown of AKT
and β-catenin, another substrate of GSK3β, did not yield any similar results, implicating that
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GSK3β activity is directly inducing the observed effect. Interestingly, in the presence of R1881
GSK3β Tyr216 phosphorylation was also increased, signifying a synergistic relationship
between GSK3β and the androgen-dependent AR signaling cascade.
Schütz et al. (2011) further complicate the story, reporting that GSK3β is necessary for
androgen-independent AR activity, though not by directly affecting the AF-1 or AF-2 activity
domains. Instead, this inhibition is in a CRM1-dependent manner, as discerned in an earlier
study [179]. CRM1 is an export receptor for substrates containing an L-rich NES, likely acting
in a RanGTP-dependent manner [182]. CRM1 activity is inhibited by leptomycin B (LMB).
Upon treatment of 22-RV1 cells with SB216763, a GSK3β inhibitor, AR was increasingly
localized in the cytoplasm and experienced a two-fold drop in the nucleus. When LMB was
added, the effects were reversed. AR transcriptional activity was also shown to drop with the
inhibitor, and was rescued by LMB. Furthermore, AR association with CRM1 was shown to
increase with SB216763, and a putative binding site was reported to be located within the C-
terminal LBD. This was found using a mutant deleted of its LBD (Schütz et al., 2010). In their
future work, Schütz et al. (2011) showed that unliganded AR in AI LNCaP lines, which was
localized to the nucleus, is exported upon application of SB216763 in a CRM1-dependent
manner, rescued by LMB. Decreased AR signaling with GSK3β was also shown in vivo using
a tumor-engrafted chick choriallantoic membrane model. Of note, knockdown (shRNA) or
long-term inhibition (SB216763) reduced the nuclear and cellular levels of AR respectively.
Mazor et al (2004) showed similar data, suggesting that GSK3β may also play a role in
maintaining stability of the AR protein.
The evidence clearly indicates that GSK3β plays a crucial role in regulation of AR; however
the nature of that role is highly controversial. Upregulation of GSK3β has been shown to be
associated with an elevated Gleason grade [180], which would suggest that support of AR
signaling would be likely. Moreover, as Gleason grade often indicates increased risk for AICaP
progression [182], however, GSK3β is also a target of AKT for Ser9 phsophorylation, which
deactivates its kinase activity. Thus it would seem detrimental that GSK3β induction and
reduced inhibition of the PI-3K pathway occur concurrently, as is the situation in several AICaP
lines such as 22-RV1. It may be important to note that while Salas et al. (2004) and Wang et al.
(2004) made liberal usage of overexpression models, while Liao et al. (2004), Schütz et al (2010)
and Schütz et al. (2011) used mainly endogenous protein. This is largely due to the nature of
the work, using GSK3β as a suppressant as opposed to studying the effects of repressed
GSK3β activity, however ectopic expression can alter a system from the in situ function. From
the presented results, it becomes apparent that endogenous GSK3β-AR interactions seem to
be AR-promoting. Mullholland et al. (2006) suggests that a baseline level of GSK3β may be
necessary for AR activity, and ectopic expression may alter the nature of the system, causing
an inhibition and suggesting that GSK3β Tyr216 phosphorylation may ultimately be AR-
inhibitory. However, the recent results by Schütz et al. (2011) contradict this, while results by
Mazor et al. (2004) indicate that overexpression of GSK3β in a system with active endogenous
GSK3β, such as 22-RV1 cells, has little effect. The mechanism outlined by Schütz et al. (2010)
may be key to note: GSK3β could have a higher affinity for CRM1, thereby preferentially
preventing AR export and thus promoting AR transactivation. Further, it would seem that
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these interaction play a different role in ligand-dependent and AI disease, which may suggest
a role in promoting the progression of CaP to an AI state. Alteration of GSK3β or alteration of
its interactions in situ may play an important role in regulating GSK3β function with respect
to CaP, as it has been shown to play a wide variety of tumour-suppressing and oncogenic roles
when in different environments. Thus, a change in cellular context may be key to its role in
CaP progression.
4.3. PI-3K/Wnt/AR Axis
The Wnt pathway and the PI-3K have both been implicated in CaP progression. Additionally,
crosstalk has been evidenced between the two systems, usually downstream of AKT. In
particular, GSK3β is a common intermediary between the Wnt and PI-3K pathways through
which crosstalk is often implicated. In the Wnt pathway, GSK3β phosphorylates β-catenin, the
central effector of the pathway, to mark it for ubiquitination and subsequent proteosomal
degradation [184]. β -catenin is a multifunctional protein that both aids in the stabilization of
the adherens junction with E-cadherin and activates transcription of Wnt target genes. Wnt
ligands activate the Wnt pathway by binding to their seven-pass transmembrane receptor
frizzled (Fzd) and its co-receptors LDL receptor related proteins 5 and 6 (LRP5/6). The Wnt
pathway is divided into the canonical Wnt pathway, which signals through β-catenin, and the
non-canonical Wnt pathway. The non-canonical Wnt pathway includes the calcium dependent
pathway and the planar cell polarity pathway, both of which play vital roles in development.
[185,186]. The canonical Wnt pathway is stimulated when a member of a subset of Wnt ligands
binds Fzd. This transduces a signal through dishevelled (Dvl) to disrupt the β-catenin
destruction complex, made up of adenomatous polyposis coli (APC), casein kinase 1 (CK1)
and GSK3 β unified by the scaffolding protein Axin. By sequential phosphorylation, ubiqui‐
tination and degradation in the presence of an active destruction complex, β-catenin is
maintained at reasonable levels. Upon stimulation by a Wnt ligand, GSK3βis deactivated by
Dvl and Axin is seuestered to the membrane by the now-phosphorylated LRP5/6. This allows
β-catenin to accumulate unchecked, and translocate to the nucleus. The mechanism for β-
catenin translocation remains unclear. In order to play its role as a transcativator, β-catenin
must bind its nuclear interactor T-cell factor (TCF). In a cell unstimulated by Wnt activation,
TCF is bound to its repressor, Groucho. With Wnt activation, β-catenin displaces Groucho, and
the β-catenin/TCF complex transcribes a plethora of Wnt target genes, many of which play
oncogenic roles. In this way, β-catenin itself is a potent oncogene.
Wang et al. (2008) used castration resistant mouse models to demonstrate that AR expression
seems to be concurrently expressed with increased levels of cytoplasmic β-catenin that is
unattached to the adherens junction. This is significant because free β-catenin has the potential
to shuttle to the nucleus and activate transcription of Wnt target genes. Trucia et al. (2000)
establish a direct significance for this co-expression: β-catenin and AR can directly interact,
leading to enhanced AR signaling and hypersensitivity to androgens. In LNCaP cells β-catenin
and AR were shown to complex both in the presence and absence of androgen, but binding
was markedly enhanced in the presence of DHT. However, using a stabilized mutant of β-
catenin (β-catenin S33F) it was shown that AR activity is only enhanced in the presence of
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androgen, signifying a ligand-dependent activation. This was measured using a luciferase
reporter assay. Trucia et al. (2000) went on to show that β-catenin binds AR on its LBD, and
reduces the effects of bicalutamide on AR. This was shown to be through alteration of the AR
LBD, broadening the scope of AR-ligand interactions to include other ligands. In this way β-
catenin was show by Trucia et al. (2000) to be a co-activator of AR, providing it with increased
significance beyond its role as a coactivator of Wnt target genes with TCF. β-catenin's inter‐
action with AR were shown to be increasingly important by Mullholland et al. (2002), who
showed that the AR/β-catenin complex can serve as a vehicle for β-catenin translocation in a
ligand-dependent manner. Treatment with androgen in LNCaP cells led to colocalization of
AR and β-catenin to the nucleus. Mullholland et al. (2002) went on to show that there are several
points of overlap between β-catenin-driven and AR-driven transcription by noting several
common targets, including cell cycle proteins such as cyclin D1. Others since have showed
interaction between the two molecules, both in support [67] and in contention [47, 189]. In fact,
data by Chesire et al. (2002) indicates that ligand-dependent AR/ β-catenin interactions inhibit
β-catenn/TCF activity.
The most obvious point of crosstalk between PI-3K and Wnt is their common intermediary,
GSK3. Sharma et al. (2002) investigated the crosstalk between these two molecules and AR.
Treatment of LNCaP cells with LY294002 resulted in inhibition of AR-driven PSA expression,
demonstrating a regulation of AR activity similar to that seen by Li et al. (2001). Upon
application of LY294002, phosphorylation of AKT decreased, as did inhibitory phosphoryla‐
tion of GSK3 β. In conjunction with the lack of deactivation of GSK3 β, nuclear accumulation
of β-catenin was significantly reduced. Usage of a mutant β-catenin mutated at its GSK3
βphosphorylation site attenuated the results, showing that the modulation of AR transactiva‐
tion by the PI-3K pathway occurs through β-catenin. This finding is contradicted by Liao et al.
(2004) and Mazor et al. (2003), who demonstrate that GSK3 βis required for AR transactivation.
Liao et al (2004) showed that knockdown of β-catenin by pooled siRNA does not affect the
levels of R1881-stimulated AR transactivation as measured using a PSA-SEAP reporter
construct. Mazor et al. (2003) also show that depletion of β-catenin levels by siRNA treatment
does not inhibit transactivation by endogenous AR in 22-RV1, LNCaP and CWR-R1 cells. In
fact, they demonstrate that knockdown of β-catenin leads to increased levels of AR activity. It
is worthy to note that both Liao et al. (2004) and Mazor et al. (2003) worked with primarily
endogenous proteins, using knockdown models, and demonstrating that endogenous β-
catenin is not a co-activator of AR. Mazor et al. (2003) notes the importance of confirming
results obtained using ectopic expression with studies of endogenous protein.
For the most part, this section focuses on crosstalk through GSK3β. However, it is important
to note that AKT modulates a variety of substrates downstream of PI-3K, and a number of
these could be means for crosstalk. Hoogeboom et al. (2008) noted that FOXO interrupts β-
catenin/TCF transcription by binding and sequestering β-catenin. This type of interference
could play a role in inhibiting β-catenin/AR transcription as well, should that interaction take
place. If β-catenin Is truly a coactivator of AR, or if AR does act as a shuttle for β-catenin, a
great depth of understanding could be arrived at. In order to understand CaP progression and
the roles of the Wnt, PI-3K and AR pathways therein, these interactions must be studied and
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understood. Should β-catenin coactivate with AR, the question arises as to whether it might
do the same with FOXO. Many other proteins adapt functions based on their interactors and
β-catenin is no different, being responsible for maintaining anchorage dependence when
interacting with E-cadherin at the adherens junction. Mazor et al. (2003) had justification in
commenting that the endogenous interactions of a protein should be understood. Until the
relationships underlying β-catenin and its interactors are characterized, its role in CaP
progression will remain elusive.
5. Current therapy, implications and future directions
The reciprocal interactions and interplay between the AR and PI3K/AKT axis suggests that the
underlying mechanism potentiating CaP progression is complex and impacts the very balance
of these prosurvival pathways. Current literature shows that there is indeed crosstalk between
the AR and PI3K/AKT pathway occuring at various levels. The integration of these oncogenic
pathways potentiates CaP tumorigenesis and this is further complicated by the levels of
androgens and stage of CaP progression. In effect, the transition from AD-CaP to AI-CaP in
prostate carcinogenesis provides major clinical challenges. Androgen ablation and/or anti-
androgen therapies are only temporarily effective. Such therapies yield a hormone refractory
tumor that is essentially untreatable with the most effective standard chemotherapeutic
regimens which only increase patient survival for 2 months [191]. In this case, the pharmaco‐
logical challenge then, will be to consider the contributions from both PI3K/AKT and AR
signalling pathways throughout CaP progression [82].
The mTORC1 pathway has been a primary focus for drug development due to the discovery
of rapamycin [93]. However, selective inhibitors from this family of compounds have not
proven to be effective. Although, it seems promising to use drug combinations for the
inhibition of the main survival pathways (mTORC1, PI3K, AKT) this may incidently result in
high toxicity. The concept of intercepting signaling cross-talk with drug combinations to target
multiple nodes of integration and/or multiple kinases may be useful in controlling upstream
and downstream the PI3K pathway. In addition, the ability of the PI3K/AKT pathway to
synergistically heighten AR signaling together with non-genomic cross talk between other pro-
survival factors make targetable areas for therapy difficult. Now, with the integration of the
Wnt/β-catenin signalling pathway in AR regulation the interplay between PI3K, Wnt and AR
signaling becomes further complicated. As such, putative chemotherapeutic agents that inhibit
upstream the Wnt or PI3K signaling may pose a viable option [194].
The oncogenic role of the PI3K/AKT pathway in CaP progression is clearly evident. However,
the mechanisms underlying the interplay between PI3K and AR signaling still remains unclear.
Therefore, understanding how crosstalks are regulated in CaP progression will provide a
means by which to elucidate the complexities and contexts of AI disease that are necessary for
successful therapeutic intervention.
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